Shares of Affimed NV (NASDAQ:AFMD) fell 11.1% during mid-day trading on Friday . The company traded as low as $2.53 and last traded at $2.57, 2,433,867 shares traded hands during mid-day trading. An increase of 235% from the average session volume of 726,686 shares. The stock had previously closed at $2.89.
A number of research firms have recently issued reports on AFMD. Zacks Investment Research lowered Affimed from a “buy” rating to a “hold” rating in a research note on Thursday, August 8th. ValuEngine upgraded Affimed from a “sell” rating to a “hold” rating in a research note on Wednesday, August 28th. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $6.36.
The business has a 50 day simple moving average of $2.96 and a two-hundred day simple moving average of $3.03. The stock has a market cap of $190.91 million, a price-to-earnings ratio of -6.76 and a beta of 2.91. The company has a current ratio of 3.48, a quick ratio of 3.47 and a debt-to-equity ratio of 0.02.
Several hedge funds and other institutional investors have recently made changes to their positions in AFMD. BlackRock Inc. bought a new position in shares of Affimed in the 2nd quarter valued at about $8,399,000. Acadian Asset Management LLC grew its holdings in shares of Affimed by 3,524.2% in the 2nd quarter. Acadian Asset Management LLC now owns 2,176,604 shares of the biopharmaceutical company’s stock valued at $6,247,000 after acquiring an additional 2,116,546 shares in the last quarter. Russell Investments Group Ltd. bought a new position in shares of Affimed in the 3rd quarter valued at about $1,051,000. Stonepine Capital Management LLC grew its holdings in shares of Affimed by 41.5% in the 2nd quarter. Stonepine Capital Management LLC now owns 715,754 shares of the biopharmaceutical company’s stock valued at $2,054,000 after acquiring an additional 210,018 shares in the last quarter. Finally, Canada Pension Plan Investment Board bought a new position in shares of Affimed in the 2nd quarter valued at about $574,000. Institutional investors own 51.01% of the company’s stock.
Affimed Company Profile (NASDAQ:AFMD)
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead product candidate is AFM13, a natural killer cell (NK-cell) TandAb, which is in Phase 2a clinical study of relapsed CD30-positive lymphoma and Phase 1b clinical study of anti-PD-1 antibody Keytruda (pembrolizumab) in patients with relapsed Hodgkin lymphoma.
Receive News & Ratings for Affimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed and related companies with MarketBeat.com's FREE daily email newsletter.